A DNA tetrahedron-based ferroptosis-suppressing nanoparticle: superior delivery of curcumin and alleviation of diabetic osteoporosis

Abstract

Diabetic osteoporosis (DOP) is a significant complication that poses continuous threat to the bone health of patients with diabetes; however, currently, there are no effective treatment strategies. In patients with diabetes, the increased levels of ferroptosis affect the osteogenic commitment and differentiation of bone mesenchymal stem cells (BMSCs), leading to significant skeletal changes. To address this issue, we aimed to target ferroptosis and propose a novel therapeutic approach for the treatment of DOP. We synthesized ferroptosis-suppressing nanoparticles, which could deliver curcumin, a natural compound, to the bone marrow using tetrahedral framework nucleic acid (tFNA). This delivery system demonstrated excellent curcumin bioavailability and stability, as well as synergistic properties with tFNA. Both in vitro and in vivo experiments revealed that nanoparticles could enhance mitochondrial function by activating the nuclear factor E2-related factor 2 (NRF2)/glutathione peroxidase 4 (GPX4) pathway, inhibiting ferroptosis, promoting the osteogenic differentiation of BMSCs in the diabetic microenvironment, reducing trabecular loss, and increasing bone formation. These findings suggest that curcumin-containing DNA tetrahedron-based ferroptosis-suppressing nanoparticles have a promising potential for the treatment of DOP and other ferroptosis-related diseases.

References

1. Shanbhogue V., Mitchell D., Rosen C.& Bouxsein, M. Type 2 diabetes and the skeleton: new insights into sweet bones. Lancet. Diabetes Endocrinol. 4, 159-173 (2016).
2. Napoli, N.et al.Mechanisms of diabetes mellitus-induced bone fragility. Nat. Rev. Endocrinol. 13, 208-219 (2017).
3. Shanbhogue V. V., Hansen S., Frost M., Brixen K.& Hermann, A. P. Bone disease in diabetes: another manifestation of microvascular disease? Lancet Diabetes Endocrinol. 5, 827-838 (2017).
4. Devlin M. J.& Rosen, C. J. The bone-fat interface: basic and clinical implications of marrow adiposity. Lancet Diabetes Endocrinol. 3, 141-147 (2015).
5. Greenhill C.Shared variants for osteoporosis and T2DM. Nat. Rev. Endocrinol. 14, 627(2018).
6. Sheu A., Greenfield J., White C.& Center, J. Assessment and treatment of osteoporosis and fractures in type 2 diabetes. Trends Endocrinol. Metab. 33, 333-344 (2022).
7. Khosla S., Samakkarnthai P., Monroe D. G.& Farr, J. N. Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus. Nat. Rev. Endocrinol. 17, 685-697 (2021).
8. Hofbauer, L.et al.Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol. 10, 207-220 (2022).
9. Ru, Q.et al.Fighting age-related orthopedic diseases: focusing on ferroptosis. Bone Res. 11, 12(2023).
10. Balogh, E.et al. Iron overload inhibits osteogenic commitment and differentiation of mesenchymal stem cells via the induction of ferritin. Biochim. Biophys. Acta Mol. Basis Disease1862, 1640-1649 (2016).
11. Yang, Y.et al.Targeting ferroptosis suppresses osteocyte glucolipotoxicity and alleviates diabetic osteoporosis. Bone Res. 10, 26(2022).
12. Tong, L.et al.Current understanding of osteoarthritis pathogenesis and relevant new approaches. Bone Res. 10, 60(2022).
13. Xue, Y.et al. Alkaline “nanoswords” coordinate ferroptosis-like bacterial death for antibiosis and osseointegration. ACS Nano 17, 2711-2724 (2023).
14. Dixon, S. J.et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072 (2012).
15. Tonnus, W.et al.The role of regulated necrosis in endocrine diseases. Nat. Rev. Endocrinol. 17, 497-510 (2021).
16. Jiang, X., Stockwell, B. R.& Conrad, M. Ferroptosis: mechanisms, biology, and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266-282 (2021).
17. Mishima, E.et al. A non-canonical vitamin K cycle is a potent ferroptosis suppressor. Nature 608, 778-783 (2022).
18. Barayeu, U.et al.Hydropersulfides inhibit lipid peroxidation and ferroptosis by scavenging radicals. Nat. Chem. Biol. 19, 28-37 (2022).
19. Stockwell, B. R. Ferroptosis turns 10: emerging mechanisms, physiological functions,therapeutic applications. Cell 185, 2401-2421 (2022).
20. Tang D., Chen X., Kang R.& Kroemer, G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 31, 107-125 (2021).
21. Mao, C.et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 593, 586-590 (2021).
22. Cui, S.et al.Autophagosomes defeat ferroptosis by decreasing generation and increasing discharge of free Fe2+ in skin repair cells to accelerate diabetic wound healing. Adv. Sci. 10, e2300414(2023).
23. Liang, D.et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell 186, 2748-2764.e2722 (2023).
24. Hu, X.et al.Optineurin regulates NRF2-mediated antioxidant response in a mouse model of Paget's disease of bone. Sci. Adv. 9, eade6998 (2023).
25. Yue, L.et al.Chemotaxis‐guided self‐propelled macrophage motor for targeted treatment of acute pneumonia. Adv. Mater. 35, e2211626(2023).
26. Wang, D.et al.Cell Membrane vesicles with enriched CXCR4 display enhances their targeted delivery as drug carriers to inflammatory sites. Adv. Sci. 8, e2101562(2021).
27. Rashwan, A. K.et al.An updated and comprehensive review on the potential health effects of curcumin-encapsulated micro/nanoparticles. Crit. Rev. Food Sci. Nutr. 63, 9731-9751 (2023).
28. Chen, Z.et al.Multifaceted role of phyto-derived polyphenols in nanodrug delivery systems. Adv. Drug Deliv. Rev. 176, 113870(2021).
29. Tian, T.et al.A dynamic DNA tetrahedron framework for active targeting. Nat. Protoc. 18, 1028-1055 (2023).
30. Zhang, T.et al.Design, fabrication and applications of tetrahedral DNA nanostructure-based multifunctional complexes in drug delivery and biomedical treatment. Nat. Protoc. 15, 2728-2757 (2020).
31. Li, J.et al.Modulation of the crosstalk between schwann cells and macrophages for nerve regeneration: a therapeutic strategy based on multifunctional tetrahedral framework nucleic acids system. Adv. Mater. 34, e2202513(2022).
32. Ma, W.et al.Biomimetic nanoerythrosome-coated aptamer-DNA tetrahedron/ maytansine conjugates: pH-responsive and targeted cytotoxicity for HER2- positive breast cancer. Adv. Mater. 34, e2109609(2022).
33. Wang, Y.et al.Tetrahedral framework nucleic acids can alleviate taurocholateinduced severe acute pancreatitis and its subsequent multiorgan injury in mice. Nano Lett. 22, 1759-1768 (2022).
34. Zhang, Y.et al.Multi-targeted antisense oligonucleotide delivery by a framework nucleic acid for inhibiting biofilm formation and virulence. Nanomicro Lett. 12, 74(2020).
35. Gao, Y.et al.A LYsosome-activated tetrahedral nanobox for encapsulated sirna delivery. Adv. Mater. 34, e2201731(2022).
36. Li, S.et al.A tetrahedral framework DNA-based bioswitchable mirna inhibitor delivery system: application to skin anti-aging. Adv. Mater. 34, e2204287(2022).
37. Zhang, T.et al.Myelosuppression alleviation and hematopoietic regeneration by tetrahedral-framework nucleic-acid nanostructures functionalized with osteogenic growth peptide. Adv. Sci. 9, e2202058(2022).
38. Liu, Z.et al.Suppression of lipopolysaccharide-induced sepsis by tetrahedral framework nucleic acid loaded with quercetin. Adv. Funct. Mater. 32, 2204587(2022).
39. Yan, R.et al. Typhaneoside-tetrahedral framework nucleic acids system: mitochondrial recovery and antioxidation for acute kidney injury treatment. ACS Nano 17, 8767-8781 (2023).
40. Zhao, Y.et al.Effects of puerarin-loaded tetrahedral framework nucleic acids on osteonecrosis of the femoral head. Small 19, e2302326 (2023).
41. Gao, S.et al.Tetrahedral framework nucleic acids induce immune tolerance and prevent the onset of type 1 diabetes. Nano Lett. 21, 4437-4446 (2021).
42. Li, Y.et al.Tetrahedral framework nucleic acid-based delivery of resveratrol alleviates insulin resistance: from innate to adaptive immunity. Nanomicro Lett. 13, 86(2021).
43. Li, Y.et al. Tetrahedral framework nucleic acids ameliorate insulin resistance in type 2 diabetes mellitus via the PI3K/Akt Pathway. ACS Appl. Mater. Interfaces 13, 40354-40364 (2021).
44. Wu, T.et al.METTL3-m(6) A methylase regulates the osteogenic potential of bone marrow mesenchymal stem cells in osteoporotic rats via the Wnt signalling pathway. Cell Prolif. 55, e13234(2022).
45. Li, Y.et al.Advanced glycation end products inhibit the osteogenic differentiation potential of adipose-derived stem cells by modulating Wnt/β-catenin signalling pathway via DNA methylation. Cell Prolif. 53, e12834(2020).
46. Peng, S.et al.LncRNA-AK137033 inhibits the osteogenic potential of adiposederived stem cells in diabetic osteoporosis by regulating Wnt signaling pathway via DNA methylation. Cell Prolif. 55, e13174(2022).
47. Salhotra A., Shah H. N., Levi B.& Longaker, M. T. Mechanisms of bone development and repair. Nat. Rev. Mol. Cell Biol. 21, 696-711 (2020).
48. Li, S.et al.Bioswitchable delivery of microRNA by framework nucleic acids: application to bone regeneration. Small 17, e2104359 (2021).
49. Eberhardt J., Santos-Martins D., Tillack, A. F. & Forli, S. AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings. J. Chem. Inf. Model 61,3891-3898 (2021).
50. Drake, Z. C., Seffernick, J. T.& Lindert, S. Protein complex prediction using Rosetta, AlphaFold, and mass spectrometry covalent labeling. Nat. Commun. 13, 7846(2022).
51. Gao, M., Nakajima, An,D., Parks, J. M. & Skolnick, J. AF2Complex predicts direct physical interactions in multimeric proteins with deep learning. Nat. Commun. 13, 1744(2022).
52. Tevlin, R.et al.Pharmacological rescue of diabetic skeletal stem cell niches. Sci. Transl. Med. 9, eaag2809 (2017).
53. Zhang, Y.et al.Co-delivery of doxorubicin and curcumin via cRGD-peptide modified PEG-PLA self-assembly nanomicelles for lung cancer therapy. Chin. Chem. Lett. 33, 2507-2511 (2022).
54. Zhang, C.et al.Oral colon-targeted mucoadhesive micelles with enzymeresponsive controlled release of curcumin for ulcerative colitis therapy. Chin. Chem. Lett. 33, 4924-4929 (2022).
55. Zhang, T., Tian, T.& Lin, Y. Functionalizing framework nucleic-acid-based nanostructures for biomedical application. Adv. Mater. 34, e2107820(2022).
56. Shi, S.et al.Amelioration of osteoarthritis via tetrahedral framework nucleic acids delivering microrna‐124 for cartilage regeneration. Adv. Funct. Mater. 33, 202305558(2023).
57. Zhang T.,et al Nanomaterials targeting toll‐like receptor 4 prevent bisphosphonate‐ related osteonecrosis of the jaw via regulating mitochondrial homeostasis in macrophages. Adv. Funct. Mater. 33, 202213401(2023).
58. Zhou B. O., Yue R., Murphy M. M., Peyer, J. G. & Morrison, S. J. Leptin-receptorexpressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 15, 154-168 (2014).
59. Sun, Y.et al.The long noncoding RNA lnc-ob1 facilitates bone formation by upregulating Osterix in osteoblasts. Nat. Metab. 1, 485-496 (2019).
60. Lutz T. A.Mammalian models of diabetes mellitus, with a focus on type 2 diabetes mellitus. Nat. Rev. Endocrinol. 19, 350-360 (2023).
61. Kallai, I.et al.Microcomputed tomography-based structural analysis of various bone tissue regeneration models. Nat. Protoc. 6, 105-110 (2011).

Funding

En Luo ([e-mail]) or Yunfeng Lin ([e-mail])